Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study
Data from available studies suggest that the presence of ST-elevation myocardial infarction (STEMI) may be associated with delayed and attenuated ticagrelor bioavailability and effect compared with non-ST-elevation myocardial infarction (NSTEMI). In a single-center, prospective, observational trial...
Saved in:
| Published in | PloS one Vol. 12; no. 10; p. e0186013 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
12.10.2017
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1932-6203 1932-6203 |
| DOI | 10.1371/journal.pone.0186013 |
Cover
| Abstract | Data from available studies suggest that the presence of ST-elevation myocardial infarction (STEMI) may be associated with delayed and attenuated ticagrelor bioavailability and effect compared with non-ST-elevation myocardial infarction (NSTEMI).
In a single-center, prospective, observational trial 73 patients with myocardial infarction (STEMI n = 49, NSTEMI n = 24) underwent a pharmacokinetic and pharmacodynamic assessment after a 180 mg ticagrelor loading dose (LD). Ticagrelor and its active metabolite (AR-C124910XX) plasma concentrations were determined with liquid chromatography tandem mass spectrometry, and their antiplatelet effect was measured with the VASP assay and multiple electrode aggregometry.
During the first six hours after ticagrelor LD, STEMI patients had 38% and 34% lower plasma concentration of ticagrelor and AR-C124910XX, respectively, than NSTEMI (ticagrelor AUC(0-6): 2491 [344-5587] vs. 3991 [1406-9284] ng*h/mL; p = 0.038; AR-C124910XX AUC(0-6): 473 [0-924] vs. 712 [346-1616] ng*h/mL; p = 0.027). STEMI patients also required more time to achieve maximal concentration of ticagrelor (tmax: 4.0 [3.0-12.0] vs. 2.5 [2.0-6.0] h; p = 0.012). Impaired bioavailability of ticagrelor and AR-C124910XX seen in STEMI subjects was associated with diminished platelet inhibition in this group, which was most pronounced during the initial hours of treatment.
Plasma concentrations of ticagrelor and AR-C124910XX during the first hours after ticagrelor LD were one third lower in STEMI than in NSTEMI patients. This reduced and delayed ticagrelor bioavailability was associated with weaker antiplatelet effect in STEMI.
ClinicalTrials.gov identifier: NCT02602444 (November 09, 2015). |
|---|---|
| AbstractList | Data from available studies suggest that the presence of ST-elevation myocardial infarction (STEMI) may be associated with delayed and attenuated ticagrelor bioavailability and effect compared with non-ST-elevation myocardial infarction (NSTEMI).BACKGROUNDData from available studies suggest that the presence of ST-elevation myocardial infarction (STEMI) may be associated with delayed and attenuated ticagrelor bioavailability and effect compared with non-ST-elevation myocardial infarction (NSTEMI).In a single-center, prospective, observational trial 73 patients with myocardial infarction (STEMI n = 49, NSTEMI n = 24) underwent a pharmacokinetic and pharmacodynamic assessment after a 180 mg ticagrelor loading dose (LD). Ticagrelor and its active metabolite (AR-C124910XX) plasma concentrations were determined with liquid chromatography tandem mass spectrometry, and their antiplatelet effect was measured with the VASP assay and multiple electrode aggregometry.METHODSIn a single-center, prospective, observational trial 73 patients with myocardial infarction (STEMI n = 49, NSTEMI n = 24) underwent a pharmacokinetic and pharmacodynamic assessment after a 180 mg ticagrelor loading dose (LD). Ticagrelor and its active metabolite (AR-C124910XX) plasma concentrations were determined with liquid chromatography tandem mass spectrometry, and their antiplatelet effect was measured with the VASP assay and multiple electrode aggregometry.During the first six hours after ticagrelor LD, STEMI patients had 38% and 34% lower plasma concentration of ticagrelor and AR-C124910XX, respectively, than NSTEMI (ticagrelor AUC(0-6): 2491 [344-5587] vs. 3991 [1406-9284] ng*h/mL; p = 0.038; AR-C124910XX AUC(0-6): 473 [0-924] vs. 712 [346-1616] ng*h/mL; p = 0.027). STEMI patients also required more time to achieve maximal concentration of ticagrelor (tmax: 4.0 [3.0-12.0] vs. 2.5 [2.0-6.0] h; p = 0.012). Impaired bioavailability of ticagrelor and AR-C124910XX seen in STEMI subjects was associated with diminished platelet inhibition in this group, which was most pronounced during the initial hours of treatment.RESULTSDuring the first six hours after ticagrelor LD, STEMI patients had 38% and 34% lower plasma concentration of ticagrelor and AR-C124910XX, respectively, than NSTEMI (ticagrelor AUC(0-6): 2491 [344-5587] vs. 3991 [1406-9284] ng*h/mL; p = 0.038; AR-C124910XX AUC(0-6): 473 [0-924] vs. 712 [346-1616] ng*h/mL; p = 0.027). STEMI patients also required more time to achieve maximal concentration of ticagrelor (tmax: 4.0 [3.0-12.0] vs. 2.5 [2.0-6.0] h; p = 0.012). Impaired bioavailability of ticagrelor and AR-C124910XX seen in STEMI subjects was associated with diminished platelet inhibition in this group, which was most pronounced during the initial hours of treatment.Plasma concentrations of ticagrelor and AR-C124910XX during the first hours after ticagrelor LD were one third lower in STEMI than in NSTEMI patients. This reduced and delayed ticagrelor bioavailability was associated with weaker antiplatelet effect in STEMI.CONCLUSIONSPlasma concentrations of ticagrelor and AR-C124910XX during the first hours after ticagrelor LD were one third lower in STEMI than in NSTEMI patients. This reduced and delayed ticagrelor bioavailability was associated with weaker antiplatelet effect in STEMI.ClinicalTrials.gov identifier: NCT02602444 (November 09, 2015).CLINICAL TRIAL REGISTRATIONClinicalTrials.gov identifier: NCT02602444 (November 09, 2015). Data from available studies suggest that the presence of ST-elevation myocardial infarction (STEMI) may be associated with delayed and attenuated ticagrelor bioavailability and effect compared with non-ST-elevation myocardial infarction (NSTEMI).In a single-center, prospective, observational trial 73 patients with myocardial infarction (STEMI n = 49, NSTEMI n = 24) underwent a pharmacokinetic and pharmacodynamic assessment after a 180 mg ticagrelor loading dose (LD). Ticagrelor and its active metabolite (AR-C124910XX) plasma concentrations were determined with liquid chromatography tandem mass spectrometry, and their antiplatelet effect was measured with the VASP assay and multiple electrode aggregometry.During the first six hours after ticagrelor LD, STEMI patients had 38% and 34% lower plasma concentration of ticagrelor and AR-C124910XX, respectively, than NSTEMI (ticagrelor AUC(0-6): 2491 [344-5587] vs. 3991 [1406-9284] ng*h/mL; p = 0.038; AR-C124910XX AUC(0-6): 473 [0-924] vs. 712 [346-1616] ng*h/mL; p = 0.027). STEMI patients also required more time to achieve maximal concentration of ticagrelor (tmax: 4.0 [3.0-12.0] vs. 2.5 [2.0-6.0] h; p = 0.012). Impaired bioavailability of ticagrelor and AR-C124910XX seen in STEMI subjects was associated with diminished platelet inhibition in this group, which was most pronounced during the initial hours of treatment.Plasma concentrations of ticagrelor and AR-C124910XX during the first hours after ticagrelor LD were one third lower in STEMI than in NSTEMI patients. This reduced and delayed ticagrelor bioavailability was associated with weaker antiplatelet effect in STEMI.ClinicalTrials.gov identifier: NCT02602444 (November 09, 2015). Background Data from available studies suggest that the presence of ST-elevation myocardial infarction (STEMI) may be associated with delayed and attenuated ticagrelor bioavailability and effect compared with non-ST-elevation myocardial infarction (NSTEMI). Methods In a single-center, prospective, observational trial 73 patients with myocardial infarction (STEMI n = 49, NSTEMI n = 24) underwent a pharmacokinetic and pharmacodynamic assessment after a 180 mg ticagrelor loading dose (LD). Ticagrelor and its active metabolite (AR-C124910XX) plasma concentrations were determined with liquid chromatography tandem mass spectrometry, and their antiplatelet effect was measured with the VASP assay and multiple electrode aggregometry. Results During the first six hours after ticagrelor LD, STEMI patients had 38% and 34% lower plasma concentration of ticagrelor and AR-C124910XX, respectively, than NSTEMI (ticagrelor AUC.sub.(0-6) : 2491 [344-5587] vs. 3991 [1406-9284] ng*h/mL; p = 0.038; AR-C124910XX AUC.sub.(0-6) : 473 [0-924] vs. 712 [346-1616] ng*h/mL; p = 0.027). STEMI patients also required more time to achieve maximal concentration of ticagrelor (t.sub.max : 4.0 [3.0-12.0] vs. 2.5 [2.0-6.0] h; p = 0.012). Impaired bioavailability of ticagrelor and AR-C124910XX seen in STEMI subjects was associated with diminished platelet inhibition in this group, which was most pronounced during the initial hours of treatment. Conclusions Plasma concentrations of ticagrelor and AR-C124910XX during the first hours after ticagrelor LD were one third lower in STEMI than in NSTEMI patients. This reduced and delayed ticagrelor bioavailability was associated with weaker antiplatelet effect in STEMI. Clinical trial registration ClinicalTrials.gov identifier: NCT02602444 (November 09, 2015) Data from available studies suggest that the presence of ST-elevation myocardial infarction (STEMI) may be associated with delayed and attenuated ticagrelor bioavailability and effect compared with non-ST-elevation myocardial infarction (NSTEMI). In a single-center, prospective, observational trial 73 patients with myocardial infarction (STEMI n = 49, NSTEMI n = 24) underwent a pharmacokinetic and pharmacodynamic assessment after a 180 mg ticagrelor loading dose (LD). Ticagrelor and its active metabolite (AR-C124910XX) plasma concentrations were determined with liquid chromatography tandem mass spectrometry, and their antiplatelet effect was measured with the VASP assay and multiple electrode aggregometry. During the first six hours after ticagrelor LD, STEMI patients had 38% and 34% lower plasma concentration of ticagrelor and AR-C124910XX, respectively, than NSTEMI (ticagrelor AUC.sub.(0-6) : 2491 [344-5587] vs. 3991 [1406-9284] ng*h/mL; p = 0.038; AR-C124910XX AUC.sub.(0-6) : 473 [0-924] vs. 712 [346-1616] ng*h/mL; p = 0.027). STEMI patients also required more time to achieve maximal concentration of ticagrelor (t.sub.max : 4.0 [3.0-12.0] vs. 2.5 [2.0-6.0] h; p = 0.012). Impaired bioavailability of ticagrelor and AR-C124910XX seen in STEMI subjects was associated with diminished platelet inhibition in this group, which was most pronounced during the initial hours of treatment. Plasma concentrations of ticagrelor and AR-C124910XX during the first hours after ticagrelor LD were one third lower in STEMI than in NSTEMI patients. This reduced and delayed ticagrelor bioavailability was associated with weaker antiplatelet effect in STEMI. Background Data from available studies suggest that the presence of ST-elevation myocardial infarction (STEMI) may be associated with delayed and attenuated ticagrelor bioavailability and effect compared with non-ST-elevation myocardial infarction (NSTEMI). Methods In a single-center, prospective, observational trial 73 patients with myocardial infarction (STEMI n = 49, NSTEMI n = 24) underwent a pharmacokinetic and pharmacodynamic assessment after a 180 mg ticagrelor loading dose (LD). Ticagrelor and its active metabolite (AR-C124910XX) plasma concentrations were determined with liquid chromatography tandem mass spectrometry, and their antiplatelet effect was measured with the VASP assay and multiple electrode aggregometry. Results During the first six hours after ticagrelor LD, STEMI patients had 38% and 34% lower plasma concentration of ticagrelor and AR-C124910XX, respectively, than NSTEMI (ticagrelor AUC(0–6): 2491 [344–5587] vs. 3991 [1406–9284] ng*h/mL; p = 0.038; AR-C124910XX AUC(0–6): 473 [0–924] vs. 712 [346–1616] ng*h/mL; p = 0.027). STEMI patients also required more time to achieve maximal concentration of ticagrelor (tmax: 4.0 [3.0–12.0] vs. 2.5 [2.0–6.0] h; p = 0.012). Impaired bioavailability of ticagrelor and AR-C124910XX seen in STEMI subjects was associated with diminished platelet inhibition in this group, which was most pronounced during the initial hours of treatment. Conclusions Plasma concentrations of ticagrelor and AR-C124910XX during the first hours after ticagrelor LD were one third lower in STEMI than in NSTEMI patients. This reduced and delayed ticagrelor bioavailability was associated with weaker antiplatelet effect in STEMI. Clinical trial registration ClinicalTrials.gov identifier: NCT02602444 (November 09, 2015) Data from available studies suggest that the presence of ST-elevation myocardial infarction (STEMI) may be associated with delayed and attenuated ticagrelor bioavailability and effect compared with non-ST-elevation myocardial infarction (NSTEMI). In a single-center, prospective, observational trial 73 patients with myocardial infarction (STEMI n = 49, NSTEMI n = 24) underwent a pharmacokinetic and pharmacodynamic assessment after a 180 mg ticagrelor loading dose (LD). Ticagrelor and its active metabolite (AR-C124910XX) plasma concentrations were determined with liquid chromatography tandem mass spectrometry, and their antiplatelet effect was measured with the VASP assay and multiple electrode aggregometry. During the first six hours after ticagrelor LD, STEMI patients had 38% and 34% lower plasma concentration of ticagrelor and AR-C124910XX, respectively, than NSTEMI (ticagrelor AUC(0-6): 2491 [344-5587] vs. 3991 [1406-9284] ng*h/mL; p = 0.038; AR-C124910XX AUC(0-6): 473 [0-924] vs. 712 [346-1616] ng*h/mL; p = 0.027). STEMI patients also required more time to achieve maximal concentration of ticagrelor (tmax: 4.0 [3.0-12.0] vs. 2.5 [2.0-6.0] h; p = 0.012). Impaired bioavailability of ticagrelor and AR-C124910XX seen in STEMI subjects was associated with diminished platelet inhibition in this group, which was most pronounced during the initial hours of treatment. Plasma concentrations of ticagrelor and AR-C124910XX during the first hours after ticagrelor LD were one third lower in STEMI than in NSTEMI patients. This reduced and delayed ticagrelor bioavailability was associated with weaker antiplatelet effect in STEMI. ClinicalTrials.gov identifier: NCT02602444 (November 09, 2015). Background Data from available studies suggest that the presence of ST-elevation myocardial infarction (STEMI) may be associated with delayed and attenuated ticagrelor bioavailability and effect compared with non-ST-elevation myocardial infarction (NSTEMI). Methods In a single-center, prospective, observational trial 73 patients with myocardial infarction (STEMI n = 49, NSTEMI n = 24) underwent a pharmacokinetic and pharmacodynamic assessment after a 180 mg ticagrelor loading dose (LD). Ticagrelor and its active metabolite (AR-C124910XX) plasma concentrations were determined with liquid chromatography tandem mass spectrometry, and their antiplatelet effect was measured with the VASP assay and multiple electrode aggregometry. Results During the first six hours after ticagrelor LD, STEMI patients had 38% and 34% lower plasma concentration of ticagrelor and AR-C124910XX, respectively, than NSTEMI (ticagrelor AUC(0–6): 2491 [344–5587] vs. 3991 [1406–9284] ng*h/mL; p = 0.038; AR-C124910XX AUC(0–6): 473 [0–924] vs. 712 [346–1616] ng*h/mL; p = 0.027). STEMI patients also required more time to achieve maximal concentration of ticagrelor (tmax: 4.0 [3.0–12.0] vs. 2.5 [2.0–6.0] h; p = 0.012). Impaired bioavailability of ticagrelor and AR-C124910XX seen in STEMI subjects was associated with diminished platelet inhibition in this group, which was most pronounced during the initial hours of treatment. Conclusions Plasma concentrations of ticagrelor and AR-C124910XX during the first hours after ticagrelor LD were one third lower in STEMI than in NSTEMI patients. This reduced and delayed ticagrelor bioavailability was associated with weaker antiplatelet effect in STEMI. Clinical trial registration ClinicalTrials.gov identifier: NCT02602444 (November 09, 2015) |
| Audience | Academic |
| Author | Gorog, Diana A. Adamska, Urszula Umińska, Julia M. Sobczak, Przemysław Marszałł, Michał P. Kubica, Aldona Navarese, Eliano P. Laskowska, Ewa Sikora, Adam Skibińska, Natalia Rość, Danuta Adamski, Piotr Paciorek, Przemysław Buszko, Katarzyna Ostrowska, Małgorzata Kubica, Jacek Sikora, Joanna |
| AuthorAffiliation | 2 Department of Pharmacology and Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland 9 Department of Health Promotion, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland 3 Department of Theoretical Foundations of Biomedical Science and Medical Informatics, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland 10 National Heart & Lung Institute, Imperial College, London, United Kingdom 1 Department of Principles of Clinical Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland 4 Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland 5 Department of Medicinal Chemistry, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland 7 Chair of Dermatology, Sexually Transmitted Diseases and Immunodermatology, Faculty of Medicine, Nicolaus Copernicus University in Toruń, Poland 6 Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland 8 |
| AuthorAffiliation_xml | – name: 6 Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland – name: 8 Department of Pathophysiology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland – name: 10 National Heart & Lung Institute, Imperial College, London, United Kingdom – name: 2 Department of Pharmacology and Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland – name: 4 Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland – name: 9 Department of Health Promotion, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland – name: Medizinische Hochschule Hannover, GERMANY – name: 1 Department of Principles of Clinical Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland – name: 3 Department of Theoretical Foundations of Biomedical Science and Medical Informatics, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland – name: 5 Department of Medicinal Chemistry, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland – name: 7 Chair of Dermatology, Sexually Transmitted Diseases and Immunodermatology, Faculty of Medicine, Nicolaus Copernicus University in Toruń, Poland |
| Author_xml | – sequence: 1 givenname: Piotr orcidid: 0000-0001-9719-0987 surname: Adamski fullname: Adamski, Piotr – sequence: 2 givenname: Joanna surname: Sikora fullname: Sikora, Joanna – sequence: 3 givenname: Ewa surname: Laskowska fullname: Laskowska, Ewa – sequence: 4 givenname: Katarzyna surname: Buszko fullname: Buszko, Katarzyna – sequence: 5 givenname: Małgorzata surname: Ostrowska fullname: Ostrowska, Małgorzata – sequence: 6 givenname: Julia M. surname: Umińska fullname: Umińska, Julia M. – sequence: 7 givenname: Adam surname: Sikora fullname: Sikora, Adam – sequence: 8 givenname: Natalia surname: Skibińska fullname: Skibińska, Natalia – sequence: 9 givenname: Przemysław surname: Sobczak fullname: Sobczak, Przemysław – sequence: 10 givenname: Urszula surname: Adamska fullname: Adamska, Urszula – sequence: 11 givenname: Danuta surname: Rość fullname: Rość, Danuta – sequence: 12 givenname: Aldona surname: Kubica fullname: Kubica, Aldona – sequence: 13 givenname: Przemysław surname: Paciorek fullname: Paciorek, Przemysław – sequence: 14 givenname: Michał P. surname: Marszałł fullname: Marszałł, Michał P. – sequence: 15 givenname: Eliano P. surname: Navarese fullname: Navarese, Eliano P. – sequence: 16 givenname: Diana A. surname: Gorog fullname: Gorog, Diana A. – sequence: 17 givenname: Jacek surname: Kubica fullname: Kubica, Jacek |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29023473$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk2tr1EAUhoNU7EX_gWhAEIVmnWsy6QehFC-FQsFWvw4nk8nulNlMnJms7g_1_zh7qXRLURNCksnzvifnzDmH2V7vep1lzzGaYFrhdzdu9D3YyZCWJwiLEmH6KDvANSVFSRDdu_O8nx2GcIMQp6Isn2T7pEaEsooeZL_O3HwAb4Lrc9fljXGwAGOhMdbEZQ59m65oBgtRWx1zUNFs0GgUTL22zuemzweIRvcx5D9MnOVX10WiF7Bm50unwLcGbAI78BuHlXPKqPg3epKf5oN3YdDpdaGPc9cE7TcKsMd5MP3U6kKl8F7nIY7t8mn2uAMb9LPt_Sj7-vHD9dnn4uLy0_nZ6UWhyprEgnZVyzhBJQZGGKaci45CyQVBNarqjlcVq6FttWKUqUYAUZiVggok6oaXnB5lLze-g3VBbnckSFxzxAgXok7E-YZoHdzIwZs5-KV0YOR6wfmpBJ9KabVkDJp0cIUxZikSiKpBTQOIiApr2iWv99toYzPX7TphsDumu196M5NTt5C8pIKSKhm82Rp4933UIcq5CUpbC7124_q_GapKTERCX91DH85uS00hJZC2zKW4amUqTzmqCa_rqkzU5AEqna2eG5XatzNpfUfwdkeQmKh_ximMIcjzqy__z15-22Vf32FnGmycBWfHVSeFXfDF3Ur_KfHt3CTgZAOo1JjB604qE9cdmVIzVmIkV0N6WzS5GlK5HdIkZvfEt_5_lf0GsU1FPA |
| CitedBy_id | crossref_primary_10_1136_bmjopen_2020_043330 crossref_primary_10_1038_s41598_019_40628_0 crossref_primary_10_3390_jcm12031149 crossref_primary_10_1002_jcph_2014 crossref_primary_10_1007_s40262_020_00864_4 crossref_primary_10_1007_s12325_020_01423_w crossref_primary_10_1038_s41598_018_29619_9 crossref_primary_10_3389_fcvm_2019_00176 crossref_primary_10_3390_jcm13040965 crossref_primary_10_1161_CIRCULATIONAHA_121_056177 crossref_primary_10_1080_14656566_2017_1421634 crossref_primary_10_1007_s40262_023_01243_5 crossref_primary_10_1080_03007995_2018_1510385 crossref_primary_10_31083_j_rcm2309300 crossref_primary_10_3389_fphys_2021_663170 crossref_primary_10_3390_jcm11041124 |
| Cites_doi | 10.1160/TH16-07-0535 10.1124/dmd.110.032250 10.1080/14656566.2016.1241234 10.1093/eurheartj/ehi754 10.1016/j.ahj.2005.02.010 10.1016/j.thromres.2008.01.021 10.1136/bmjopen-2016-013218 10.1093/eurheartj/ehs215 10.1080/09537104.2016.1246714 10.5603/KP.a2017.0057 10.1016/j.thromres.2016.10.013 10.1186/s13063-015-0724-z 10.1160/TH16-09-0728 10.1016/j.jacc.2014.08.056 10.1007/s00228-012-1227-4 10.1111/bcp.13053 10.1093/eurheartj/ehv547 10.1093/eurheartj/ehv116 10.1093/eurheartj/ehv104 10.2165/11630960-000000000-00000 10.1016/j.ejphar.2014.08.009 10.1016/j.ijcard.2016.04.077 10.1111/j.1365-2710.2011.01307.x 10.1136/bmjopen-2013-004425 10.1093/eurheartj/ehv320 10.1160/TH16-08-0670 10.1093/eurheartj/eht375 10.1185/03007995.2014.880050 10.1093/eurheartj/ehs184 10.1007/s40262-015-0320-0 10.1016/j.jacc.2013.01.024 10.1016/j.jcin.2015.02.030 10.1056/NEJMoa1407024 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2017 Public Library of Science 2017 Adamski et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2017 Adamski et al 2017 Adamski et al |
| Copyright_xml | – notice: COPYRIGHT 2017 Public Library of Science – notice: 2017 Adamski et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2017 Adamski et al 2017 Adamski et al |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0186013 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Materials Science & Engineering ProQuest Central (Alumni Edition) ProQuest One Sustainability ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection ProQuest : Agricultural & Environmental Science Collection [unlimited simultaneous users] ProQuest Central Essentials Biological Science Collection ProQuest Central Technology collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection ProQuest Biological Science Collection Agricultural Science Database Health & Medical Collection (Alumni Edition) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium ProQuest advanced technologies & aerospace journals ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering collection Agricultural & Environmental Science Database Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DAOJ: Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Agricultural Science Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Open Access Full Text url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) Medicine |
| DocumentTitleAlternate | Comparison of bioavailability and antiplatelet action of ticagrelor in STEMI versus NSTEMI patients |
| EISSN | 1932-6203 |
| ExternalDocumentID | 1950425889 oai_doaj_org_article_44abbbb5c11142c1a87b0bba02871e3f PMC5638327 A509259976 29023473 10_1371_journal_pone_0186013 |
| Genre | Journal Article Comparative Study Observational Study |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PV9 PYCSY RNS RPM RZL SV3 TR2 UKHRP WOQ WOW ~02 ~KM CGR CUY CVF ECM EIF IPNFZ NPM PJZUB PPXIY PQGLB RIG BBORY PMFND 3V. 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PKEHL PQEST PQUKI PRINS RC3 7X8 ESTFP PUEGO 5PM - 02 AAPBV ABPTK ADACO BBAFP KM |
| ID | FETCH-LOGICAL-c692t-3f7d452061a42413558f3a658209079f57749addec434cb8a2c146838089b5653 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Fri Nov 26 17:12:54 EST 2021 Wed Aug 27 01:27:05 EDT 2025 Thu Aug 21 13:56:28 EDT 2025 Mon Sep 08 04:43:35 EDT 2025 Fri Jul 25 11:37:20 EDT 2025 Tue Jun 17 21:15:55 EDT 2025 Tue Jun 10 20:18:46 EDT 2025 Fri Jun 27 05:02:25 EDT 2025 Fri Jun 27 04:08:58 EDT 2025 Thu May 22 21:18:15 EDT 2025 Mon Jul 21 06:01:35 EDT 2025 Tue Jul 01 01:25:22 EDT 2025 Thu Apr 24 23:10:04 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c692t-3f7d452061a42413558f3a658209079f57749addec434cb8a2c146838089b5653 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 Competing Interests: The authors of this manuscript have the following competing interests to declare: Jacek Kubica received a consulting fee from AstraZeneca, Piotr Adamski received honoraria for lectures from AstraZeneca. All other authors have reported no relationships relevant to the contents of this paper that could be construed as a conflict of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials. |
| ORCID | 0000-0001-9719-0987 |
| OpenAccessLink | https://doaj.org/article/44abbbb5c11142c1a87b0bba02871e3f |
| PMID | 29023473 |
| PQID | 1950425889 |
| PQPubID | 1436336 |
| PageCount | e0186013 |
| ParticipantIDs | plos_journals_1950425889 doaj_primary_oai_doaj_org_article_44abbbb5c11142c1a87b0bba02871e3f pubmedcentral_primary_oai_pubmedcentral_nih_gov_5638327 proquest_miscellaneous_1954076128 proquest_journals_1950425889 gale_infotracmisc_A509259976 gale_infotracacademiconefile_A509259976 gale_incontextgauss_ISR_A509259976 gale_incontextgauss_IOV_A509259976 gale_healthsolutions_A509259976 pubmed_primary_29023473 crossref_citationtrail_10_1371_journal_pone_0186013 crossref_primary_10_1371_journal_pone_0186013 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-10-12 |
| PublicationDateYYYYMMDD | 2017-10-12 |
| PublicationDate_xml | – month: 10 year: 2017 text: 2017-10-12 day: 12 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, CA USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2017 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | R Teng (ref19) 2012; 68 R Teng (ref6) 2012; 51 R Teng (ref7) 2010; 38 J Kubica (ref5) 2017; 75 J Kubica (ref24) 2014; 30 D Alexopoulos (ref28) 2016; 55 D Venetsanos (ref30) 2017; 149 MA Mohammad (ref32) 2017; 28 J Kubica (ref10) 2016; 37 R Teng (ref20) 2012; 37 G Parodi (ref27) 2015; 65 G Parodi (ref8) 2013; 61 E Asher (ref31) 2017; 117 P Niezgoda (ref29) 2017; 117 G Montalescot (ref25) 2014; 371 J Kubica (ref16) 2015; 16 F Franchi (ref9) 2015; 8 A Kubica (ref17) 2014; 742 P Adamski (ref4) 2016; 17 TJ Meine (ref26) 2005; 149 KA Fox (ref34) 2014; 4 PG Steg (ref2) 2012; 33 D Aradi (ref3) 2015; 36 M Roffi (ref1) 2016; 37 S Husted (ref11) 2006; 27 D Aradi (ref18) 2014; 35 AA Heestermans (ref23) 2008; 122 M Koziński (ref12) 2016; 116 J Kubica (ref13) 2016; 215 K Thygesen (ref14) 2012; 33 P Adamski (ref15) 2017; 7 M Holm (ref22) 2017 JM Siller-Matula (ref33) 2016; 82 C Varenhorst (ref21) 2015; 36 22489610 - Clin Pharmacokinet. 2012 May 1;51(5):305-18 28150850 - Thromb Haemost. 2017 Apr 3;117(4):727-733 26404199 - JACC Cardiovasc Interv. 2015 Sep;8(11):1457-67 28203684 - Thromb Haemost. 2017 Apr 3;117(4):718-726 28150519 - Platelets. 2017 Nov;28(7):706-711 27128531 - Int J Cardiol. 2016 Jul 15;215:201-8 25660931 - J Am Coll Cardiol. 2015 Feb 10;65(5):511-2 26315810 - Clin Pharmacokinet. 2016 Mar;55(3):359-67 25935875 - Eur Heart J. 2015 Aug 1;36(29):1901-12 28446521 - BMJ Open. 2017 Apr 26;7(4):e013218 24393016 - Curr Med Res Opin. 2014 May;30(5):813-28 27885888 - Platelets. 2017 Jun;28(4):414-416 25199965 - Eur J Pharmacol. 2014 Nov 5;742:47-54 18455217 - Thromb Res. 2008;122(6):776-81 26491112 - Eur Heart J. 2016 Jan 14;37(3):245-52 22922416 - Eur Heart J. 2012 Oct;33(20):2569-619 15976786 - Am Heart J. 2005 Jun;149(6):1043-9 27366874 - Br J Clin Pharmacol. 2016 Nov;82(5):1343-1350 22922414 - Eur Heart J. 2012 Oct;33(20):2551-67 22367426 - Eur J Clin Pharmacol. 2012 Aug;68(8):1175-82 25896078 - Eur Heart J. 2015 Jul 14;36(27):1762-71 23500251 - J Am Coll Cardiol. 2013 Apr 16;61(15):1601-6 16476694 - Eur Heart J. 2006 May;27(9):1038-47 25175921 - N Engl J Med. 2014 Sep 11;371(11):1016-27 25925591 - Trials. 2015 Apr 29;16:198 27677394 - Expert Opin Pharmacother. 2016 Dec;17 (17 ):2291-2306 24561498 - BMJ Open. 2014 Feb 21;4(2):e004425 21967645 - J Clin Pharm Ther. 2012 Aug;37(4):464-8 20551239 - Drug Metab Dispos. 2010 Sep;38(9):1514-21 27773347 - Thromb Res. 2017 Jan;149:88-94 27628615 - Thromb Haemost. 2016 Nov 30;116(6):1140-1149 26320110 - Eur Heart J. 2016 Jan 14;37(3):267-315 24067509 - Eur Heart J. 2014 Jan;35(4):209-15 28421594 - Kardiol Pol. 2017;75(4):399-408 |
| References_xml | – volume: 116 start-page: 1140 year: 2016 ident: ref12 article-title: Which platelet function test best reflects the in vivo plasma concentrations of ticagrelor and its active metabolite? publication-title: The HARMONIC study. Thromb Haemost doi: 10.1160/TH16-07-0535 – volume: 38 start-page: 1514 year: 2010 ident: ref7 article-title: Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects publication-title: Drug Metab Dispos doi: 10.1124/dmd.110.032250 – volume: 17 start-page: 2291 year: 2016 ident: ref4 article-title: New directions for pharmacotherapy in the treatment of acute coronary syndrome publication-title: Expert Opin Pharmacother doi: 10.1080/14656566.2016.1241234 – volume: 27 start-page: 1038 year: 2006 ident: ref11 article-title: Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin publication-title: Eur Heart J doi: 10.1093/eurheartj/ehi754 – volume: 149 start-page: 1043 year: 2005 ident: ref26 article-title: Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative publication-title: Am Heart J doi: 10.1016/j.ahj.2005.02.010 – volume: 122 start-page: 776 year: 2008 ident: ref23 article-title: Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction publication-title: Thromb Res doi: 10.1016/j.thromres.2008.01.021 – volume: 7 start-page: e013218 year: 2017 ident: ref15 article-title: Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study publication-title: BMJ Open doi: 10.1136/bmjopen-2016-013218 – volume: 33 start-page: 2569 year: 2012 ident: ref2 article-title: ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation publication-title: Eur Heart J doi: 10.1093/eurheartj/ehs215 – volume: 28 start-page: 414 year: 2017 ident: ref32 article-title: Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction publication-title: Platelets doi: 10.1080/09537104.2016.1246714 – volume: 75 start-page: 399 year: 2017 ident: ref5 article-title: Anti-aggregation therapy in patients with acute coronary syndrome—recommendations for medical emergency teams. Experts’ standpoint publication-title: Kardiol Pol doi: 10.5603/KP.a2017.0057 – volume: 149 start-page: 88 year: 2017 ident: ref30 article-title: Chewed ticagrelor tablets provide faster platelet inhibition compared to integral tablets: The inhibition of platelet aggregation after administration of three different ticagrelor formulations (IPAAD-Tica) study, a randomised controlled trial publication-title: Thromb Res doi: 10.1016/j.thromres.2016.10.013 – volume: 16 start-page: 198 year: 2015 ident: ref16 article-title: Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial publication-title: Trials doi: 10.1186/s13063-015-0724-z – volume: 117 start-page: 727 year: 2017 ident: ref31 article-title: Chewing versus Swallowing Ticagrelor to Accelerate Platelet Inhibition in Acute Coronary Syndrome—the CHEERS study. For The PLATIS (Platelets and Thrombosis in Sheba) Study Group publication-title: Thromb Haemost doi: 10.1160/TH16-09-0728 – volume: 65 start-page: 511 year: 2015 ident: ref27 article-title: Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2014.08.056 – volume: 68 start-page: 1175 year: 2012 ident: ref19 article-title: Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals publication-title: Eur J Clin Pharmacol doi: 10.1007/s00228-012-1227-4 – volume: 82 start-page: 1343 year: 2016 ident: ref33 article-title: Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.13053 – volume: 37 start-page: 245 year: 2016 ident: ref10 article-title: Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial publication-title: Eur Heart J doi: 10.1093/eurheartj/ehv547 – volume: 36 start-page: 1901 year: 2015 ident: ref21 article-title: Effect of genetic variations on ticagrelor plasma levels and clinical outcomes publication-title: Eur Heart J doi: 10.1093/eurheartj/ehv116 – volume: 36 start-page: 1762 year: 2015 ident: ref3 article-title: Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention publication-title: Eur Heart J doi: 10.1093/eurheartj/ehv104 – volume: 51 start-page: 305 year: 2012 ident: ref6 article-title: Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor publication-title: Clin Pharmacokinet doi: 10.2165/11630960-000000000-00000 – volume: 742 start-page: 47 year: 2014 ident: ref17 article-title: Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction publication-title: Eur J Pharmacol doi: 10.1016/j.ejphar.2014.08.009 – volume: 215 start-page: 201 year: 2016 ident: ref13 article-title: Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors publication-title: Int J Cardiol doi: 10.1016/j.ijcard.2016.04.077 – volume: 37 start-page: 464 year: 2012 ident: ref20 article-title: Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers publication-title: J Clin Pharm Ther doi: 10.1111/j.1365-2710.2011.01307.x – volume: 4 start-page: e004425 year: 2014 ident: ref34 article-title: Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score publication-title: BMJ Open doi: 10.1136/bmjopen-2013-004425 – volume: 37 start-page: 267 year: 2016 ident: ref1 article-title: 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) publication-title: Eur Heart J doi: 10.1093/eurheartj/ehv320 – volume: 117 start-page: 718 year: 2017 ident: ref29 article-title: Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study publication-title: Thromb Haemost doi: 10.1160/TH16-08-0670 – volume: 35 start-page: 209 year: 2014 ident: ref18 article-title: Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention publication-title: Eur Heart J doi: 10.1093/eurheartj/eht375 – volume: 30 start-page: 813 year: 2014 ident: ref24 article-title: Cangrelor: an emerging therapeutic option for patients with coronary artery disease publication-title: Curr Med Res Opin doi: 10.1185/03007995.2014.880050 – volume: 33 start-page: 2551 year: 2012 ident: ref14 article-title: Third universal definition of myocardial infarction publication-title: Eur Heart J doi: 10.1093/eurheartj/ehs184 – volume: 55 start-page: 359 year: 2016 ident: ref28 article-title: Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study publication-title: Clin Pharmacokinet doi: 10.1007/s40262-015-0320-0 – volume: 61 start-page: 1601 year: 2013 ident: ref8 article-title: Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2013.01.024 – volume: 8 start-page: 1457 year: 2015 ident: ref9 article-title: Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation publication-title: JACC Cardiovasc Interv doi: 10.1016/j.jcin.2015.02.030 – year: 2017 ident: ref22 article-title: Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose publication-title: Platelets – volume: 371 start-page: 1016 year: 2014 ident: ref25 article-title: Prehospital ticagrelor in ST-segment elevation myocardial infarction publication-title: N Engl J Med doi: 10.1056/NEJMoa1407024 – reference: 23500251 - J Am Coll Cardiol. 2013 Apr 16;61(15):1601-6 – reference: 21967645 - J Clin Pharm Ther. 2012 Aug;37(4):464-8 – reference: 20551239 - Drug Metab Dispos. 2010 Sep;38(9):1514-21 – reference: 22922414 - Eur Heart J. 2012 Oct;33(20):2551-67 – reference: 25935875 - Eur Heart J. 2015 Aug 1;36(29):1901-12 – reference: 25660931 - J Am Coll Cardiol. 2015 Feb 10;65(5):511-2 – reference: 15976786 - Am Heart J. 2005 Jun;149(6):1043-9 – reference: 22922416 - Eur Heart J. 2012 Oct;33(20):2569-619 – reference: 27677394 - Expert Opin Pharmacother. 2016 Dec;17 (17 ):2291-2306 – reference: 22489610 - Clin Pharmacokinet. 2012 May 1;51(5):305-18 – reference: 24561498 - BMJ Open. 2014 Feb 21;4(2):e004425 – reference: 28421594 - Kardiol Pol. 2017;75(4):399-408 – reference: 22367426 - Eur J Clin Pharmacol. 2012 Aug;68(8):1175-82 – reference: 27366874 - Br J Clin Pharmacol. 2016 Nov;82(5):1343-1350 – reference: 25896078 - Eur Heart J. 2015 Jul 14;36(27):1762-71 – reference: 28446521 - BMJ Open. 2017 Apr 26;7(4):e013218 – reference: 27128531 - Int J Cardiol. 2016 Jul 15;215:201-8 – reference: 27885888 - Platelets. 2017 Jun;28(4):414-416 – reference: 28150519 - Platelets. 2017 Nov;28(7):706-711 – reference: 25175921 - N Engl J Med. 2014 Sep 11;371(11):1016-27 – reference: 24393016 - Curr Med Res Opin. 2014 May;30(5):813-28 – reference: 26320110 - Eur Heart J. 2016 Jan 14;37(3):267-315 – reference: 25925591 - Trials. 2015 Apr 29;16:198 – reference: 26315810 - Clin Pharmacokinet. 2016 Mar;55(3):359-67 – reference: 27773347 - Thromb Res. 2017 Jan;149:88-94 – reference: 25199965 - Eur J Pharmacol. 2014 Nov 5;742:47-54 – reference: 26404199 - JACC Cardiovasc Interv. 2015 Sep;8(11):1457-67 – reference: 26491112 - Eur Heart J. 2016 Jan 14;37(3):245-52 – reference: 28203684 - Thromb Haemost. 2017 Apr 3;117(4):718-726 – reference: 28150850 - Thromb Haemost. 2017 Apr 3;117(4):727-733 – reference: 27628615 - Thromb Haemost. 2016 Nov 30;116(6):1140-1149 – reference: 18455217 - Thromb Res. 2008;122(6):776-81 – reference: 16476694 - Eur Heart J. 2006 May;27(9):1038-47 – reference: 24067509 - Eur Heart J. 2014 Jan;35(4):209-15 |
| SSID | ssj0053866 |
| Score | 2.3737404 |
| Snippet | Data from available studies suggest that the presence of ST-elevation myocardial infarction (STEMI) may be associated with delayed and attenuated ticagrelor... Background Data from available studies suggest that the presence of ST-elevation myocardial infarction (STEMI) may be associated with delayed and attenuated... Background Data from available studies suggest that the presence of ST-elevation myocardial infarction (STEMI) may be associated with delayed and attenuated... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0186013 |
| SubjectTerms | Adenosine - analogs & derivatives Adenosine - blood Adenosine - pharmacokinetics Adenosine - pharmacology Aged Analysis Bioavailability Biological Availability Biology and Life Sciences Blood platelets Blood Platelets - drug effects Cardiology Cardiovascular disease Care and treatment Chromatography Clinical medicine Complications and side effects Coronary vessels Dosage and administration Drug dosages Drug therapy Electrocardiography Female Heart attack Heart attacks Humans Internal medicine Liquid chromatography Male Mass spectrometry Mass spectroscopy Medicine Medicine and Health Sciences Metabolites Middle Aged Myocardial infarction Non-ST Elevated Myocardial Infarction - blood Non-ST Elevated Myocardial Infarction - drug therapy Patient outcomes Patients Pharmaceutical sciences Pharmacodynamics Pharmacokinetics Pharmacology Plasmas (physics) Platelet Aggregation Inhibitors - blood Platelet Aggregation Inhibitors - pharmacokinetics Prospective Studies Purinergic P2Y Receptor Antagonists - pharmacokinetics Purinergic P2Y Receptor Antagonists - pharmacology ST Elevation Myocardial Infarction - blood ST Elevation Myocardial Infarction - drug therapy Thrombosis Ticagrelor |
| SummonAdditionalLinks | – databaseName: DAOJ: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9RAEF_knnwR61dPq64iqNC0uWST3fh2FksVVLCt9C3s7iV6EJPD3An9Q_1__M1mExopnA8e3Et2siTztb_ZzMwy9gKrhlG2sIGOI4kARehAm7QM0tjOtC0QgLhD-z5-Sk_OxYeL5OLKUV-UE9a1B-4YdyiENvgldkZVn5hASRMao0OC-kVckvcNs7APpjofDCtOU18oF8vZoZfLwaqpi4NwphCFxKOFyPXrH7zyZFU17XWQ8-_MyStL0fFtdstjSD7vnn2H3SjqO2zHW2nLX_lW0q_vst9HwzGDvCm5WTb6l15WXW_uS67rBf6UUAjECQHyrsqBSGmLG6E4onm-rLnvvtpy2rblp2cBVaU7mfIfl1gNScsqEJYwG3eVZq6bOthO-obPOTjQV3zu88YMG8W62ue0l1EVgWNFwV033Hvs_Pjd2dFJ4A9yCGyaResgLuVCJBGggxb0HS9JVBlrYB-SnMzKBBg0I0drRSysURpyFqmKVagyA8QZ32cTPHOxy_hCJkZqKNhCAelJKEdUIIKDRkmTAGxMWdxLNbe-yzkdtlHl7tOdRLTTCSknXci9LkxZMNy16rp8bKF_Swoz0FKPbncBmpt7zc23ae6UPSV1y7uC18HT5HNgOLwScOKUPXcU1KejpkSgb3rTtvn7z1__gej0y4jopScqG7DDal98gXei_l8jyr0RJbyNHQ3vknH0XGlzOkYYfl-pDHf2BnP98LNhmCal5L66aDaORtB2WqSm7EFnXwNnowygUkhwXI4sb8T68Ui9_O7apCdYWuCAHv4PWT1iNyPCcy6VaY9N1j83xWOg0bV54hzPH4zXjdM priority: 102 providerName: Directory of Open Access Journals – databaseName: Public Health Database dbid: 8C1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjR1da9RAcNETxJdi60dTq64iqNBtc9kku_FFzsNShSrYVvoWdjebehCTa3Mn9If6f5zZ7EUjxXpwL9lJSOZrZ2bng5AXsGtoaaxhikcCHJRYMaXTkqXcjJWx4IC4oX2Hn9KDk_jjaXLqA26tT6tc6USnqIvGYIx8D8eVAn9Jmb2dnzOcGoWnq36Exk1yC2tAkcPltE_xAFlOU18ux8V4z1Nnd97UdjccS_BF-GA7cl37e908mldNe5Xh-Xf-5B8b0v5dsuYtSTrpSL9Obth6g9w-9GflG2Tdi21LX_ne0q_vkZ_Tfu4gbUqqZ436oWZV16z7kqq6gD9mGIIJChSlXdkDgmLMG3xzcO_prKa-HWtLMY5Lj44Zlqk7ItPvl7A9IttVAFiCHLmr-OS6qdn1oG_ohAIyViWgO7TRfeRYVTsUgxuVZQ4rlrr2uPfJyf774-kB85MdmEmzaMF4KYo4icCWUDEe7CWJLLkCYwiIGIqsTMAozVDzmpjHRksVGSwR4zKUmQYTlD8gI3hnu0loIRItFHBcIcH0E7HSkQWXDlhM6ASsj4DwFYFz49ue4_SNKndneQLcn45eObJF7tkiIKy_a961_bgG_h3yTg-LTbvdhebiLPc6II_h5eCXmDEWMIMsSKFDrVWIXqvlZUCeIuflXQVsr3ryCRh18ElgOAbkuYPAxh01ZgadqWXb5h8-f_0PoKMvA6CXHqhsAB1G-WoM-CZsCDaA3B5Agvoxg-VNlJMVVtr8t6DCnSvZuXr5Wb-MD8Vsv9o2SwcTY3wtkgF52Ilaj9koAyszFoBxMRDCAeqHK_Xsm-ubnsBeAxpp69-v9YjcidB0c1lL22S0uFjax2B4LvQTp11-AUfUh9o priority: 102 providerName: ProQuest |
| Title | Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29023473 https://www.proquest.com/docview/1950425889 https://www.proquest.com/docview/1954076128 https://pubmed.ncbi.nlm.nih.gov/PMC5638327 https://doaj.org/article/44abbbb5c11142c1a87b0bba02871e3f http://dx.doi.org/10.1371/journal.pone.0186013 |
| Volume | 12 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELe27oUXxPhat1EMQgKkpUrjpHaQEOqqlYG0gbYV9S2y3WRUypLStIj-ofw_3DlORFDRVql5iC9f57vz72zfHSGvYNRQQsfakczj4KD40pGqnzh9pntSx-CAmKJ9Z-f907H_eRJMtkhVs9UysNjo2mE9qfEi7f76sf4ACv_eVG3gveqi7jzP4q7bE-BjsG2yA2OTh3J-5tfrCqDdZvUSUYvT91xmg-n-d5fGYGVy-teWuzVP82ITLP13d-Vfw9XoAblvcSYdlIKxS7bi7CHZtZpc0Dc23fTbR-T3sC5FSPOEqlkuf8pZWubvXlOZTeGPmw4BlUIn0zISAklxGhzcdfD46SyjNkNrQXFql15eORi5bvqd3qxhxERJTIEwAdUyZ_HOWZ45t5O-owMKHKiiQo9orurJZJkeUZzvSGPHsCKmJmPuYzIenVwNTx1b7MHR_dBbOizhUz_wAF5IH9f6gkAkTAI-8lzw38MkAJwaojHWPvO1EtLTGDXGhCtCBaiUPSEteOd4j9ApDxSXIIRTAWiQ-1J5MXh5IHVcBQBI2oRVvRppmwkdC3KkkVne4-ARlZ0UoSxEVhbaxKmvmpeZQG6hP0aBqWkxj7c5kS-uI2sWIh9eDn6B7mFMM6iH4MpVSrroyMYsaZPnKG5RGRRbW6NoADgPPgmwZJu8NBSYyyPDzULXclUU0acv3-5AdHnRIHptiZIc2KGlDdCAb8IcYQ3KwwYlWCTdaN5D5ai4UkRYahjGBiFCuLJSmM3NL-pmvCluAMzifGVofJxy80SbPC31q-asFwLw9DlwnDc0r8H6Zks2-25SqQcw_ICR2r_Dcw_IPQ8hndnNdEhay8UqfgaAdKk6ZJtPOBzFsIfH0ccO2Tk-Of960TFTPB1jg_4A5nGToQ |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1fb9MwELdGJwEviI0_KwxmEAiQlq2N8xdpQt3YtLK1oK1Dewu265RKISlNC-qX41vwfbhznEDQxHhZpb7EF8s5n-9-Z_vuCHkGVkMEUkmLM9sHB8XhFhdebHlMtrlU4IDoon29vnd45rw7d8-XyI8yFgavVZY6USvqYSZxj3wby5WCfAVB-Gby1cKqUXi6WpbQ4Ka0wnBHpxgzgR1HavEdXLh8p_sW5vu5bR_sD_YOLVNlwJJeaM8sFvtDx7XBrnEHD5lcN4gZB8Nst8BxDGMXAFKIWkA6zJEi4LbEcCUWtIJQABxi0O81sgywg8GqWt7d7384KW0BaBPPMwF7zG9vG_nYmmSp2mq1A_CGWM0g6roBlXVoTJIsvwj6_n2D8w-TeHCb3DJYlnYK4VshSypdJdd75rR-lawYxZHTlya79as75OdeVfmQZjEV44x_4-OkSBe-oDwdwh_vOAIIBpmiReAFkuKu-2iqkmxKxyk1CWFzijvJ9HRgYaC8FjP6ZQEGGgU_AcIYpkg_xZ7TLLUuJ31NOxSYUQahbtJMVHvXPNmkuL2SKEtzRVGdoPcuObuSWb9HGjBmtUbo0HeFz0HmhwGAT9_hwlbgVIKQ-8IF_NMkrJzgSJrE61j_I4n0aaIPDlgxXxGKRWTEokms6q1JkXjkEvpdlJ2KFtOG6wfZdBQZLRQ5MDj4ubKNIdSwGgNftITgLfSbFYubZAMlLypicCvlF3UAVsInAXRtkqeaAlOHpHg3acTneR5133_8D6LTkxrRC0MUZ8AOyU08CHwTpiSrUa7XKEEBylrzGq6Tkit59FtVwJvl2rm4-UnVjJ3ifcNUZXNN4-AOnx00yf1iqVWctUPAuY4PHPdri7DG-npLOv6sM7e7YO1AJz7497A2yI3DQe84Ou72jx6SmzYCSX2Hap00ZtO5egQweCYeG11DyaerVm-_AEGryH4 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGkSZeEBuXFQYzCARIy5rm5gQJodJRrYwNtAvaW7Bdp1QKSWlaUP8a_4P_wzmOEwiaGC-r1Jf4JEqOP5-LfS6EPAatIUKppMVdh4GD4nGLiyCxAld2uVTggOimfQeHwd6p9_bMP1shP6pcGAyrrGSiFtSjXOIeeQfblQK-wjDqJCYs4sPu4NX0q4UdpPCktWqnUUJkXy2_g_tWvBzuwlw_cZzBm5P-nmU6DFgyiJy55SZs5PkO6DTu4QGT74eJy0EpOzY4jVHig3EUoQSQnutJEXJHYqqSG9phJMAUcuG5V8hV5jIbw8nCfh1eAnIkCEyqnsu6HYOMnWmeqR27G4If5DZUoe4YUOuF1jTNi_OM3r9jN_9QhoMb5LqxYmmvhN0aWVHZOlk9MOf062TNiIyCPjN1rZ_fJD_7dc9DmidUTHL-jU_SslD4kvJsBH-MbgTzF9BEy5QLJMX99vFMpfmMTjJqSsEWFPeQ6fGJhSnyGmD0yxJUM0I-BcIEJkhfxSdneWZdTPqC9igwo0o_3aa5qHetebpNcWMlVZbmiqK6NO8tcnopc36btOCd1QahI-YLxgHtoxDMTuZx4ShwJwHeTPhg-bSJW01wLE3Jdez8kcb6HJGB61XOV4ywiA0s2sSq75qWJUcuoH-N2KlpsWC4vpDPxrGRP7EHLwc_X3YxeRrWYciELQS30WNWbtImW4i8uMy-rcVe3AODEj4JjNY2eaQpsGhIhstvzBdFEQ_ff_wPouOjBtFTQ5TkwA7JTSYIfBMWI2tQbjYoQfTJxvAGrpOKK0X8W0jAndXaOX_4YT2MD8VIw0zlC03j4d6eE7bJnXKp1Zx1IrBwPQYcZ41F2GB9cySbfNY1233QcyAN7_77tbbIKgi1-N3wcP8eueagBamDpzZJaz5bqPtg_87FAy1oKPl02ZLtF0oZxeU |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+bioavailability+and+antiplatelet+action+of+ticagrelor+in+patients+with+ST-elevation+myocardial+infarction+and+non-ST-elevation+myocardial+infarction%3A+A+prospective%2C+observational%2C+single-centre+study&rft.jtitle=PloS+one&rft.au=Adamski%2C+Piotr&rft.au=Sikora%2C+Joanna&rft.au=Laskowska%2C+Ewa&rft.au=Buszko%2C+Katarzyna&rft.date=2017-10-12&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=12&rft.issue=10&rft.spage=e0186013&rft_id=info:doi/10.1371%2Fjournal.pone.0186013&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |